AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
News & Events
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities…
AbCellera Reports Q1 2023 Business Results
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
Presented at AACR 2023: AbCellera’s T-cell engager platform 1
AbCellera on TEDx Vancouver: How to Find the Drugs of the Future
Infographic: From Sample to Lead in Just 4 Weeks
Featured on AWS Healthcare & Life Sciences Web Day: Combating COVID-19 1
Carl Hansen, AbCellera CEO sits down with Fierce Biotech’s Rebecca Willumson1

Presented at AACR 2023: AbCellera’s
T-cell engager platform
Talks & Presentations

SynBioBeta 2019

PepTalk 2020

Festival of Biologics 2020

LifeSciences BC’s Blakes Breakfast

SFU-UBC PDA Career Networking Night

PEGS Virtual Interactive Global Summit







BIO Digital 2020







Antibody Engineering and Therapeutics Europe Virtual






16th Annual PEGS Boston







US East Coast Antibody Therapeutics e-Xchange


18th Annual Discovery on Target







BC Cancer Research Day







Discovery to Commercialization


The 11th Annual Don Rix Distinguished Keynote Address



PEGS Europe Virtual






Antibody Engineering and Therapeutics U.S.



Keystone Symposia on Molecular & Cellular Biology






PepTalk Virtual 2021



Providence Health Care Innovation Seminar



Molecular Med Tri-Con Virtual



Biocom’s Global Life Science Partnering Conference




LifeSciences BC Access to Innovation






BIO Oncology Virtual Partnering Event



BIO Immunology Virtual Partnering Event


BIO-Europe Spring Digital


Festival of Biologics USA


Antibody Engineering & Therapeutics Asia Virtual Scientific Forum


Biologics Europe: Online




PEGS Boston Virtual






US East Coast Antibody Therapeutics Xchange




SynBioBeta Biopharma Day






Antibody Engineering & Therapeutics Europe



MaRS Impact Health






West Coast Antibody Therapeutics Xchange



Antibody Discovery, Selection and Screening Digital Week



Discovery on Target


PEGS Europe



Festival of Biologics Europe


European Antibody Therapeutics Xchange



Antibody Engineering & Therapeutics U.S.


PepTalk




Life Sciences BC Access to Innovation






Festival of Biologics USA



Gordon Research Conference: Antibody Biology and Engineering






AACR Annual Meeting






PEGS Boston






MaRS Impact Health







The Data Effect: How to Build a Digital Society


BIO 2022






BioProcess International




BIO-Europe


Festival of Biologics Europe


SITC Annual Meeting





PEGS Europe





Antibody Engineering & Therapeutics USA




JPM Annual Healthcare Meeting 2023






Lorne Proteins 2023




Keystone Symposium: Multispecific Immune Cell Engagers for Cancer Immunotherapy




Fierce Business Development & Licensing Summit 2023



Festival of Biologics 2023






AACR Annual Meeting



Cell Culture Engineering XVIII





PEGS 2023




Antibody Engineering & Therapeutics Europe




Longwood Healthcare Leaders Spring MIT Conference




Immuno-Oncology Summit Europe


ISPE Biotechnology Conference



PDA/FDA Joint Regulatory Conference




World Bispecific Summit



Festival of Biologics Europe





PEGS Europe
Antibody Engineering & Therapeutics USA
SynBioBeta 2019
Although the natural immune repertoire is a boundless source of therapeutic antibodies, merely sampling from it will not capture its full diversity. Maia Smith, co-creator of AbCellera’s proprietary data visualization tool Celium™ presented “Visualize scale and diversity in natural antibody discovery”. Celium™ is an intuitive and interactive software that visualizes antibodies discovered on AbCellera’s platform, and not only sorts them by clonal ties, functionality, and developability, but relates them to similar antibody sequences in our repertoire.
Watch Maia’s talk here.




PepTalk 2020
AbCellera has successfully completed several antibody discovery programs targeting GPCRs and ion channels. Marta presented insights on AbCellera’s innovative approach in her talk “Against Nature: How to Hack Immune Systems to Discover Antibodies that Target Complex Membrane Proteins”




Festival of Biologics 2020
Using clever immunization strategies and screening millions of single B cells, AbCellera has found and validated hundreds of ultra-low frequency and highly diverse antibodies. Senior Research Scientist, Christopher Williamson presented “Ultra-rare but there: natural and diverse antibodies against high homology targets” in the Protein Engineering stream at this year’s Festival of Biologics.






LifeSciences BC’s Blakes Breakfast
The Blakes Breakfast Speaking Series is LifeSciences BC’s longest-standing event series, bringing together local, national and multinational life science companies. This month, a panel of speakers contributed to a discussion themed “Understanding the COVIDcampaign-pages/bispecifics/-19 virus and how BC is leading the fight”. Senior Research Scientist Kathryn Westendorf presented AbCellera’s efforts in her talk “Making an Antibody-Based Therapeutic in 60 Days: High-Throughput Discovery Applied to a Rapid Pandemic Response Platform”.




SFU-UBC PDA Career Networking Night
Co-founder, Véronique Lecault, will be addressing Metro Vancouver’s postdoctoral research community and presenting exciting career opportunities at AbCellera.





PEGS Virtual Interactive Global Summit
Co-founder and Head of Business Development, Kevin Heyries, Ph.D. will be presenting “From Patient Screen to Phase I in 90 Days: Identifying Neutralizing Antibodies for the World’s First Study of a Potential COVIDcampaign-pages/bispecifics/-19 Antibody Treatment”, in the Making Antibodies Rapidly to Combat Pandemic Viruses session on Tuesday, June 23, 2020.






BIO Digital 2020
AbCellera will be at BIO Digital 2020. If you are in the business of biologics, we are looking forward to connecting. Find out how our full technology stack can streamline and accelerate your lead generation. Get in touch via the BIO Portal or email us.
Antibody Engineering and Therapeutics Europe Virtual
Sherie will be presenting on “Amplifying antibody diversity: Single-cell screening combined with immune repertoire sequencing from humanized mice”.


16th Annual PEGS Boston
AbCellera’s co-founder and Head of Business Development, Kevin Heyries, Ph.D., will be presenting ‘Amplifying antibody diversity with Single-cell screening and immune repertoire sequencing’.
High throughput single-cell screening is enabling the rapid generation of large, diverse antibody sequence datasets. By combining immune repertoire sequencing with functionally validated single-cell data, we further expand antibody diversity accessible for lead identification. Celium™, AbCellera’s interactive software, interprets these complex datasets using dynamic visual networks to guide the selection of valuable antibodies. This unparalleled ability to both generate and visualize highly curated large datasets dramatically expands the pool of potential therapeutic candidates.






US East Coast Antibody Therapeutics e-Xchange
Kevin Heyries, Ph.D., co-founder and Head of Business Development will be presenting ‘Amplifying antibody diversity: Single-cell screening combined with immune repertoire sequencing from humanized mice’.
18th Annual Discovery on Target
AbCellera’s co-founder and Head of Business Development, Kevin Heyries, Ph.D., will be presenting ‘Amplifying antibody diversity with Single-cell screening and immune repertoire sequencing’.
High throughput single-cell screening is enabling the rapid generation of large, diverse antibody sequence datasets. By combining immune repertoire sequencing with functionally validated single-cell data, we further expand antibody diversity accessible for lead identification. Celium™, AbCellera’s interactive software, interprets these complex datasets using dynamic visual networks to guide the selection of valuable antibodies. This unparalleled ability to both generate and visualize highly curated large datasets dramatically expands the pool of potential therapeutic candidates.


BC Cancer Research Day
Stefanie Žentelis will be representing AbCellera at the BC Cancer Research Day 2020, hosted by the BC Cancer Graduate Student and Postdoctoral Fellow Society.



Discovery to Commercialization
Organized by UBC Faculty of Medicine and Vancouver Coastal Health Research Institute, Discovery to Commercialization is a series of education and networking events that aim to raise awareness and knowledge around the therapeutic commercialization process. Lucas Kraft will be representing AbCellera and presenting at the session ‘Building Bridges: How Researchers Came Together During COVIDcampaign-pages/bispecifics/-19’.


The 11th Annual Don Rix Distinguished Keynote Address
Genome BC presents its 11th Annual Don Rix Distinguished Keynote Address: Battle Lines: Fighting COVIDcampaign-pages/bispecifics/-19 at the intersection of policy, treatment and prevention. This virtual event brings together the unique perspectives and insights from three BC leaders who have made an indelible impact in the fight against COVIDcampaign-pages/bispecifics/-19.
Speakers include BC’s Provincial Health Officer, Dr. Bonnie Henry, along with Dr. Mel Krajden, Medical Director at the BC Centre for Disease Control’s Public Health Laboratory and Dr. Carl Hansen, CEO of AbCellera.









PEGS Europe Virtual
Christopher Williamson, Ph.D., Senior Scientist and Project Lead will be presenting “Amplifying Antibody Diversity – Single-Cell Screening Combined with Repertoire Sequencing from Humanized Mice” at the Protein & Antibody Engineering Summit.







Antibody Engineering and Therapeutics U.S.
Kevin Heyries, Ph.D. will be presenting “From Patient Sample to Antibody Lead in Three Weeks: A Real-Time Response to COVIDcampaign-pages/bispecifics/-19″ at the virtual Antibody Engineering & Therapeutics U.S.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/-19, click here.






Keystone Symposia on Molecular & Cellular Biology
Bo Barnhart, Ph.D. presented Combating COVIDcampaign-pages/bispecifics/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days at Antibodies and Vaccines as Drugs for COVIDcampaign-pages/bispecifics/-19.











PepTalk Virtual 2021
Kevin Heyries, Ph.D. will be presenting “From Patient Sample to Antibody Lead in Three Weeks: A Real-Time Response to COVIDcampaign-pages/bispecifics/-19″ at PepTalk 2021.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/-19, click here.






Providence Health Care Innovation Seminar
Bo Barnhart, Ph.D. will be presenting Combating COVIDcampaign-pages/bispecifics/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days at Providence Health Care’s Innovation Seminar Series.










Molecular Med Tri-Con Virtual
Bo Barnhart, Ph.D. will be presenting “From Patient Sample to Antibody Lead in Three Weeks: A Real-Time Response to COVIDcampaign-pages/bispecifics/-19″ at the Molecular Med Tri-Con in the COVIDcampaign-pages/bispecifics/-19 Vaccines & Biotherapeutics track.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/-19, click here.










Biocom’s Global Life Science Partnering Conference
Biocom’s 11th Annual Global Life Science Partnering Conference is an exclusive global partnering forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies.



LifeSciences BC Access to Innovation
Carl Hansen, PH.D., CEO of AbCellera will be presenting at LifeSciences BC’s 6th annual Access to Innovation Conference.











BIO Oncology Virtual Partnering Event
Do you have oncology targets in your pipelines? AbCellera is looking forward to connecting with you at the BIO Oncology Virtual Partnering Event.






BIO Immunology Virtual Partnering Event
Looking to accelerate your immunology pipelines? Connect with us at the BIO Immunology Virtual Partnering Event!



BIO-Europe Spring Digital
Are you in the business of biologics? We look forward to connecting at BIO-Europe Spring.


Festival of Biologics USA
Christopher Williamson, Ph.D., Senior Research Scientist and Project Lead will be presenting “Amplifying antibody diversity with single-cell screening and immune repertoire sequencing” at the Festival of Biologics USA.






Antibody Engineering & Therapeutics Asia Virtual Scientific Forum
Kevin Heyries, Ph.D., will be presenting “Combating COVIDcampaign-pages/bispecifics/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days” at the Antibody Engineering & Therapeutics Asia Virtual Scientific Forum.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/-19, click here.


Biologics Europe: Online
Stefanie Zentelis, Ph.D., will be presenting “Combating COVIDcampaign-pages/bispecifics/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days” at Biologics Europe: Online.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/-19, click here.





PEGS Boston Virtual
Bo Barnhart, Ph.D., will be presenting will be presenting “Combating COVIDcampaign-pages/bispecifics/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days” at PEGS Boston Virtual.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/-19, click here.











US East Coast Antibody Therapeutics Xchange
Kevin Heyries, Ph.D., co-founder and Head of Business Development will be hosting a roundtable discussion ‘Next generation antibody discovery platforms—Challenges & Opportunities‘ at the US East Coast Antibody Therapeutics Xchange.






SynBioBeta Biopharma Day
Ester Falconer, Ph.D., Chief Technology Officer, will be participating in a panel discussion on ‘The Promise of Antibody Treatments Across Disease States‘ at SynBioBeta’s first ever BioPharma Day.




Antibody Engineering & Therapeutics Europe
Kevin Heyries, Ph.D., will be presenting “Amplifying antibody diversity with single-cell screening and immune repertoire sequencing” at Antibody Engineering & Therapeutics Europe.






MaRS Impact Health
Véronique Lecault, Ph.D., Co-founder and Chief Operating Officer, will be participating in a roundtable session discussing how health companies are building, scaling and tackling adoption challenges today in Canada.






West Coast Antibody Therapeutics Xchange
Kevin Heyries, Ph.D., cofounder and Head of Business Development will be hosting a roundtable discussion ‘Next generation antibody discovery platforms—Challenges & Opportunities‘ at the US West Coast Antibody Therapeutics Xchange.






Antibody Discovery, Selection and Screening Digital Week
Valentine de Puyraimond, MSc, will be presenting “Combating COVIDcampaign-pages/bispecifics/-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days” at Antibody Discovery, Selection and Screening Digital Week.
For more information on AbCellera’s response to COVIDcampaign-pages/bispecifics/-19, click here






Discovery on Target
Erica Lovett, Research Scientist at AbCellera, will be presenting “Enduring solutions to the evolving COVIDcampaign-pages/bispecifics/-19 crisis: Discovery of a potent human antibody that neutralizes SARS-CoVcampaign-pages/cd3/campaign-pages/cd3/-2 and its variants” at Discovery on Target in the Antibodies Against Membrane Protein Targets – Part 2 session on September 29 at 5:55pm EST.








PEGS Europe
Erica Lovett, Research Scientist at AbCellera, will be presenting “Enduring solutions to the evolving COVIDcampaign-pages/bispecifics/-19 crisis: Discovery of a potent human antibody that neutralizes SARS-CoVcampaign-pages/cd3/campaign-pages/cd3/-2 and its variants” at PEGS Europe in the Engineering Antibodies stream on November 3rd at 12:40pm CET.







Festival of Biologics Europe
Erica Lovett, Research Scientist at AbCellera, will be presenting “Enduring solutions to the evolving COVIDcampaign-pages/bispecifics/-19 crisis: Discovery of a potent human antibody that neutralizes SARS-CoVcampaign-pages/cd3/campaign-pages/cd3/-2 and its variants” at Festival of Biologics Europe in the Protein Engineering stream on November 9 at 4:50pm CET.
Roza Bidshahri, Senior Research Scientist and BD Liaison at AbCellera, will be hosting a roundtable discussion on Next Generation Antibody Discovery Platforms – Challenges and Opportunities on November 9 at 11:30am CET.








European Antibody Therapeutics Xchange
Roza Bidshari, Ph.D., Senior Research Scientist and BD Liaison, will be hosting a roundtable discussion ‘Next generation antibody discovery platforms—Challenges & Opportunities‘ at the European Antibody Therapeutics Xchange.






Antibody Engineering & Therapeutics U.S.
Roza Bidshahri, Senior Research Scientist and BD Liaison at AbCellera, will be presenting “Tackling transmembrane targets with Tetrahymena” at Antibody Engineering & Therapeutics on December 13th at 1:45pm PST.







Life Sciences BC Access to Innovation
Murray McCutcheon, VP of Corporate Development at AbCellera, will be participating in a fireside chat on Seizing the Opportunity for BC’s Life Sciences Sector at Life Sciences BC’s 7th annual Access to Innovation Conference.







Festival of Biologics USA
Tim Jacobs, Director of Molecular Design & Engineering at AbCellera, will be presenting “Discover and precision-engineer bispecifics with antibodies from any source using integrated discovery, computational, and engineering technologies” at Festival of Biologics USA on March 9th at 4:50pm PST.








Gordon Research Conference: Antibody Biology and Engineering
Valentine de Puyraimond, Research Scientist at AbCellera, will be presenting “Keeping Pace with a Pandemic: An Integrated Technology Stack to Discover and Develop Antibody Treatments” at the GRC on Antibody Biology and Engineering.






AACR Annual Meeting
Bo Barnhart, VP, Translational Research at AbCellera, will be presenting a poster at the AACR Annual Meeting.













PEGS Boston
AbCellera will be presenting at PEGS Boston on May 3rd at 10am EST in the Difficult-to-Express Proteins track and on May 5 at 9:30am EST in the Engineering Bispecific Antibodies track.






MaRS Impact Health
Carl Hansen, CEO, will be participating in a panel discussion on Decentralizing Biotech at MaRS Impact Health.













The Data Effect: How to Build a Digital Society
Murray McCutcheon, VP, Corporate Development at AbCellera, will be participating in a panel discussion on Unlocking Data’s Applications through AI at The Data Effect: How to Build a Digital Society.



BIO 2022
AbCellera will be at BIO 2022. Get in touch via the BIO Portal and join our company presentation on June 14 at 11:45am PST in Theater 3 to learn how AbCellera’s antibody discovery technology aims to deliver lead candidates with a higher probability of success, faster.









BioProcess International
AbCellera will be presenting at BioProcess International on September 29th at 4:30pm EST in the Manufacturing Strategies & Bioprocessing 4.0 track.











BIO-Europe
AbCellera will be at BIO-Europe. If you are in the business of biologics, we are looking forward to connecting. Get in touch via the BIO Portal.




Festival of Biologics Europe
AbCellera will be presenting “Discover and precision-engineer cancer bispecifics with integrated discovery, computational, and engineering technologies” at Festival of Biologics Europe on November 2nd at 2:20pm CET.
We will also be hosting a roundtable discussion on Overcomning Challenges in Next Generation Immune Cell Engager Design and Development on November 2nd at 11:30am CET.





SITC Annual Meeting
AbCellera will be presenting a poster at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.









PEGS Europe
Raffi Tonikian, Head of Target Product Profile Integration at AbCellera, will be presenting “Streamline T cell engager discovery with diverse CD3 antibodies and an integrated bispecific engineering platform” at PEGS Europe on November 13th at 12:15pm CET.





Antibody Engineering & Therapeutics USA
AbCellera will be presenting a poster at Antibody Engineering & Therapeutics 2022.





JPM Annual Healthcare Meeting 2023
AbCellera will be at the JPM Annual Healthcare Meeting 2023. Join our company presentation on January 11 at 2:15pm PST to learn how AbCellera’s antibody discovery technology aims to deliver lead candidates with a higher probability of success, faster.











Lorne Proteins 2023
AbCellera will be sponsoring the 48th Lorne Conference on Protein Structure & Function.






Keystone Symposium: Multispecific Immune Cell Engagers for Cancer Immunotherapy
Raffi Tonikian, Director, Translational Biomarkers, will be presenting “Streamlining T-cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine” at the Keystone Symposia on Multispecific Immune Cell Engagers for Cancer Immunotherapy.




Fierce Business Development & Licensing Summit 2023
Anne Stevens, AbCellera’s VP of Business Development, will be participating in the panel discussion “Advance your Assets: Strategies for Negotiating and Evaluating Platform Deals” at Fierce’s BD&L Summit on March 14 at 4pm PST.






Festival of Biologics 2023
AbCellera will be presenting a talk on March 21 at 3:40pm PST in the mAbs track at Festival of Biologics 2023.






AACR Annual Meeting
AbCellera will be presenting two posters at AACR 2023:
– Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies (presented by Bo Barnhart, VP, Translational Research)
See the abstract
– Breaking barriers to access intracellular targets with T-cell engagers: Discovery of diverse, developable, and ultra-specific antibodies against a MAGE-A4 pMHC (presented by Raffi Tonikian, Director, Translational Biomarkers)
See the abstract






Cell Culture Engineering XVIII
AbCellera will be sponsoring the Early Careers Pre-Conference, and presenting two posters at Cell Culture Engineering XVIII.
Véronique Lecault, Director & COO, will be presenting on AbCellera’s pandemic response.
Swapnil Bhargava, SVP, CMC Development and GMP Manufacturing, will be presenting “Streamlining T-cell engager development with diverse, fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine”.



PEGS 2023
AbCellera will be presenting at PEGS on May 18 at 2:35pm EST in the Engineering Bispecific Antibodies track.





Antibody Engineering & Therapeutics Europe
AbCellera will be presenting a poster: Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies at Antibody Engineering & Therapeutics Europe.




Longwood Healthcare Leaders Spring MIT Conference
Carl Hansen, AbCellera’s co-founder and CEO, will be participating in a panel discussion on Accelerating Drug Development at the Longwood Healthcare Leaders Spring MIT Conference.











Immuno-Oncology Summit Europe
AbCellera will be presenting a poster: Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies at Immuno-Oncology Summit Europe.







ISPE Biotechnology Conference
AbCellera will be sponsoring and attending the 2023 ISPE Biotechnology Conference in Dublin, Ireland. Connect with us to learn about our opportunities in Process Development lab and Clinical Manufacturing.


PDA/FDA Joint Regulatory Conference
Andy Clark, Director of Digital Quality, will be presenting on “Undertaking Data Governance to Enable End-to-End Data Capability” at the PDA/FDA Joint Regulatory Conference on September 19th.





World Bispecific Summit
Raffi Tonikian, Director of Translational Biomarkers, will be presenting “Adopting a Biomarker-Driven Bispecific Antibody Development” at the World Bispecific Summit.






Festival of Biologics Europe
AbCellera will be presenting at Festival of Biologics Europein Basel, Switzerland.








Antibody Engineering & Therapeutics USA
AbCellera will be presenting at Antibody Engineering & Therapeutics USA in San Diego, California.



